GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
This article was originally published in The Gold Sheet
Executive Summary
As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.